Cross-Sector entity
HeartBeam is most often covered alongside CareCloud, which appears in 3 of these 3 stories. Coverage clusters in earnings, which accounts for 2 of those 3, with the remainder spread across 1 other category. We currently track 3 Cross-Sector stories that mention HeartBeam, all published on March 13, 2026.
3 verified stories tracked
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
HeartBeam is most often covered alongside CareCloud, which appears in 3 of these 3 stories. Coverage clusters in earnings, which accounts for 2 of those 3, with the remainder spread across 1 other category. We currently track 3 Cross-Sector stories that mention HeartBeam, all published on March 13, 2026. Each carries 15 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HeartBeam. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle reveals a significant acceleration in AI-driven operational efficiency and product innovation across healthcare, aviation, and enterprise services. Key developments include CareCloud's successful automation of patient scheduling and HeartBeam's FDA-cleared AI diagnostic software, signaling a shift from experimental AI to core revenue-generating applications.
CareCloud achieved its first profitable year since its 2014 IPO, driven by its AI Center of Excellence and strategic acquisitions. Meanwhile, HeartBeam and Vuzix are pivoting toward high-margin software and engineering services, signaling a broader trend of hardware-to-SaaS transitions.
The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
